ICU Medical, Inc. - 10-Q Filing Summary
Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: The Company develops, manufactures, and markets disposable medical devices, primarily for intravenous (I.V.) therapy and critical care. Key products include the CLAVE connector system, custom I.V. systems, and critical care devices (catheters, angiography kits) produced under a 20-year Manufacturing, Commercialization and Development Agreement (MCDA) with Hospira, Inc.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2006 |
Six Months Ended June 30, 2006 |
Six Months Ended June 30, 2005 |
|---|---|---|---|
| Total Revenue | $51,425 | $100,206 | $67,778 |
| Net Sales | $50,891 | $98,348 | $65,779 |
| Gross Profit | $23,074 | $44,424 | $31,558 |
| Gross Margin % (of Net Sales) | 45.3% | 45.2% | 48.0% |
| Operating Income | $8,503 | $17,693 | $12,251 |
| Net Income | $6,292 | $12,658 | $9,156 |
| Diluted EPS | $0.40 | $0.82 | $0.61 |
| Cash & Liquid Investments | $100,467 (as of June 30, 2006) | ||
| Net Cash from Operating Activities | $14,367 (Six Months 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 26.4% year-over-year for the six months ended June 30, 2006 ($100.2M vs. $67.8M). This was driven primarily by the full six-month impact of the MCDA with Hospira, which contributed $38.6M in revenue compared to $13.2M in the prior year period.
- Customer Concentration: Sales to Hospira, Inc. accounted for 77% of total revenue in the first six months of 2006, up from 69% in the same period in 2005.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased to $22.8M (22% of revenue) from $17.6M (26% of revenue) in the prior year, reflecting increased compensation, bonuses, and facility expansion costs. Research and development (R&D) expenses more than doubled to $3.9M from $1.7M due to new product initiatives.
- Inventory: Inventory levels rose to $18.5M from $15.4M at year-end 2005, largely due to building buffer stock for the relocation of manufacturing operations from San Clemente and Connecticut to Salt Lake City and Mexico.
- Accounting Change: The Company adopted SFAS 123(R) effective January 1, 2006, requiring fair value recognition of stock-based compensation. This resulted in $0.3M of expense for the six months ended June 30, 2006.
Guidance, Outlook, and Risks
- Manufacturing Relocation: The Company is in the process of moving molding and automated assembly to Salt Lake City and manual assembly to Mexico. These moves are expected to be completed by the first half of 2007. Management anticipates production interruptions and quality risks during this transition.
- Capital Expenditures: Estimated capital expenditures for 2006 are approximately $14.5 million, primarily for facility improvements in Salt Lake City and Mexico.
- Stock Repurchase Plan: In July 2006, the Company adopted a plan to purchase up to $2 million of common stock initially, followed by up to $1 million per month for a year, subject to market conditions.
- Legal Proceedings:
- ICU Medical v. Alaris: A July 2006 court order interpreted certain patent claims in a manner that could impair enforcement against Alaris (owned by Cardinal Health). The Company intends to appeal.
- Medegen v. ICU Medical: A July 2006 lawsuit alleges infringement of Medegen's patents by ICU's CLC 2000 and Tego products. Management believes there is no significant financial exposure.
- Market Risks: Significant dependence on Hospira (77% of revenue); potential price erosion due to competition; risks associated with international expansion and currency fluctuations (Euro exposure); and reliance on low interest rates for investment income.
Investor Verification Checklist
- Hospira Dependency: Verify the stability of the MCDA and the risk of Hospira reducing inventory or negotiating lower prices, given they represent 77% of revenue.
- Patent Litigation Status: Monitor the appeal process regarding the July 2006 court order in the Alaris case and the defense strategy in the Medegen lawsuit.
- Manufacturing Transition: Assess the progress and potential disruptions of the facility relocations to Salt Lake City and Mexico scheduled for completion in 2007.
- Margin Trends: Track gross margins as the Company integrates lower-margin critical care products and manages rising raw material (resin) and labor costs.
- Cash Flow Utilization: Review the execution of the new stock repurchase plan and capital expenditure spending against the $14.5M estimate.